JP2023507764A5 - - Google Patents

Info

Publication number
JP2023507764A5
JP2023507764A5 JP2022537866A JP2022537866A JP2023507764A5 JP 2023507764 A5 JP2023507764 A5 JP 2023507764A5 JP 2022537866 A JP2022537866 A JP 2022537866A JP 2022537866 A JP2022537866 A JP 2022537866A JP 2023507764 A5 JP2023507764 A5 JP 2023507764A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
gaboxadol
administering
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507764A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065801 external-priority patent/WO2021127308A1/en
Publication of JP2023507764A publication Critical patent/JP2023507764A/ja
Publication of JP2023507764A5 publication Critical patent/JP2023507764A5/ja
Pending legal-status Critical Current

Links

JP2022537866A 2019-12-18 2020-12-18 １ｐ３６欠失症候群の治療的処置のためのガボキサドール Pending JP2023507764A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949551P 2019-12-18 2019-12-18
US62/949,551 2019-12-18
PCT/US2020/065801 WO2021127308A1 (en) 2019-12-18 2020-12-18 GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME

Publications (2)

Publication Number Publication Date
JP2023507764A JP2023507764A (ja) 2023-02-27
JP2023507764A5 true JP2023507764A5 (https=) 2023-12-25

Family

ID=76439052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537866A Pending JP2023507764A (ja) 2019-12-18 2020-12-18 １ｐ３６欠失症候群の治療的処置のためのガボキサドール

Country Status (10)

Country Link
US (1) US11364228B2 (https=)
EP (1) EP4051272A4 (https=)
JP (1) JP2023507764A (https=)
KR (1) KR20220114572A (https=)
CN (1) CN114786669A (https=)
AU (1) AU2020405060A1 (https=)
CA (1) CA3164635A1 (https=)
IL (1) IL293924A (https=)
MX (1) MX2022007715A (https=)
WO (1) WO2021127308A1 (https=)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
BRPI0410857A (pt) 2003-06-25 2006-07-04 Lundbeck & Co As H método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2010015037A1 (en) 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
EP2334299A1 (en) 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
EP3129506A4 (en) * 2014-04-09 2017-12-27 Lineagen, Inc. Genetic markers associated with chromosomal deletion and duplication syndromes
RS62007B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用

Similar Documents

Publication Publication Date Title
TW576743B (en) Extended release formulations of erythromycin derivatives
TW389696B (en) Accelerated release composition containing bromocriptine
BR112020008128A2 (pt) comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos
CA3107624C (en) Composition for eradicating helicobacter pylori
KR20240032789A (ko) 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2022521233A5 (https=)
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
JP4786127B2 (ja) 色素沈着改善治療薬
JP2024540439A5 (https=)
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2023507764A5 (https=)
JP2024531799A5 (https=)
US20040152733A1 (en) Duloxetine for treatment of hot flashes
JP2025511402A5 (https=)
TW202404616A (zh) 鼠李糖在製備用於治療或預防神經退行性疾病的藥物中的用途、藥物組合物及其應用
JP2025522146A5 (https=)
JP2022540917A5 (https=)
KR20230016006A (ko) 포르피린증의 예방 또는 치료제
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
JP2024506041A5 (https=)
JP2023533472A5 (https=)
WO2022097764A1 (ko) 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물
US20200061053A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
EP4070793A1 (en) Pharmaceutical composition, complementary kit and application thereof